MEETINGS

Thursday, April 30
RESIDENT LECTURES
PGY 1—4 and Child and Adolescent Psychiatry Residents: Please see weekly didactic notice emails from the Education Office for scheduled topics and presenters.

THIRD YEAR MEDICAL STUDENTS

Thursday, April 30
In the morning (Time TBA) Neurology Exam

Friday, May 1
In the morning (Time TBA) Psychiatry NBME

HAPPY BIRTHDAY
to Broke Cole/Apr 28, Dr. Caroline Brozyna/Apr 29 and Deborah Ward/May 2!!!
IN THE KNOW!!!

2015 FACULTY & STAFF CAMPAIGN

The Morsani College of Medicine’s faculty and staff make up about one sixth of ALL of the faculty and staff at USF, making it impossible for the University to reach its goal without our help. We are currently at 55 percent participation, and our goal is to reach 100 percent by the end of June 2015. It’s important to remember that every dollar does make a difference. Please consider giving back to our department, and see firsthand the impact this campaign has on our day-to-day experiences at USF Health.

Below are our priority funds identified by the leadership:

250061 – Child Development Center Operating Fund
430010 – Psychiatry Operating Fund
256048 – Center for Infant & Child Development
256072 – Daniel Sprehe Memorial, USF Forensic Psychiatry
256260 – Robert Roskamp Chair in Biological Psychiatry

You can make a gift to any fund within the USF System and your gift will count towards our department’s participation goal. To make your gift today, please click the link below, or for a paper contribution form, contact Paul DeCosta.

www.USF.edu/FSCC
Now Enrolling – Mild Alzheimer’s disease

This is a double-blind, placebo-controlled study to test the safety and effectiveness of an anti-amyloid antibody administered subcutaneously as a disease-modifying treatment in patients age 50 - 90 with mild AD. Stable dose of approved medications for AD will be permitted at study entry. Patients will undergo brain MRI exams for monitoring safety and response to study treatment. They will also undergo safety and cognitive testing. Patients must have a person with whom they are regular contact, who can accompany them to study visits. Please call Kathy at (813)974-7006 to make a referral.

Principal Investigator: Jean Fils, MD

T-FORCE study: Investigational Medication for Children and Adolescents with Tourette’s Disorder

The primary purpose of this research study is to determine the safety and tolerability of an investigational medication (NBI-98854) for Tourette syndrome. Each child will be evaluated to determine his or her eligibility to participate in the research study. Each participant who qualifies will receive the investigational medication, study-related medical exams, and laboratory tests at no cost. As some of the medical appointments can be lengthy, many forms of entertainment will be available to participants at his or her study visits. Compensation for time and travel is also available. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Investigational Medication (Ecopipam) for Children and Adolescents with Tourette’s Disorder

The purpose of this research study is to evaluate an experimental drug called ecopipam in children ages 7 to 17 with Tourette’s syndrome. The drug has not been approved by the FDA. There will be eight study visits and six telephone call visits, totally about 4 months. For the first two weeks of the Study Drug Part 1, subject will slowly increase the number of tablets (50/50 placebo or ecopipam) and stay on a stable dose for 2 weeks before discontinuing the study drug. After at least 10 days, subject will be re-examined. Study Drug Part 3 will be very much like Study Drug Part 1: for the first two weeks of the Study Drug Part 3, the subject will slowly increase the number of tablets (50/50 placebo or ecopipam, opposite of part 1) and stay on a stable dose for 2 weeks before discontinuing the study drug. Compensation for time and travel is also available. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Continued on page 4
Investigational Medication (SD-809 [Deutetrabenazine]) for Adolescents with Tourette’s Disorder

The purpose of this research study is to evaluate an investigational medication (SD-809 [Deutetrabenazine]) that may help reduce tics. Tetrabenazine is a drug that has been approved in several European Union countries and Canada for the treatment of various movement disorders including tics, and it has also been approved by the US Food and Drug Administration (FDA) for the treatment of involuntary movements associated with Huntington Disease. SD-809 is an investigational drug, meaning it has not been approved by the FDA. SD-809 has the same action as tetrabenazine; however, SD-809 is broken down in the body more slowly than tetrabenazine. These differences in breakdown and release may mean that SD-809: 1) may be taken fewer times a day and 2) may react differently in the body compared to tetrabenazine. Study participants must be 12-18 years old and diagnosed with Tourette’s Disorder. The clinical trial will involve taking the experimental drug for an 8-week period. Study participants will be compensated for their time. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Investigational Medication (Bitopertin) for Adults with OCD

The purpose of this research study is to evaluate an investigational medication (bitopertin) for adults with OCD, and determine if patients treated with bitopertin and a selective serotonin reuptake inhibitor (SSRI) may experience fewer symptoms compared with those treated with SSRI only, a currently recommended treatment for OCD. To prequalify for this study, patients must be between the ages of 18 and 65 years, currently taking medication for OCD, and continue to have symptoms of OCD while on medication. Additional eligibility requirements will be discussed with all potential participants prior to enrollment. Reimbursement for travel may also be provided. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Cognitive-Behavioral Therapy (CBT) for Anxiety Disorders in Children with Autism Spectrum Disorder Research Study

The purpose of this research study is to examine the efficacy of a manualized cognitive behavioral therapy to treat anxiety disorders in children with autism spectrum disorders. Therapy sessions last approximately one hour a week for sixteen weeks. In addition, participants will be involved in a number of anxiety and developmental assessments free of charge. Children ages 6-17 years old are eligible to participate. Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch, PhD

Continued on page 5
RESEARCH HAPPENINGS!

Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder

The purpose of this research study is to assess the efficacy of a form of Cognitive Behavioral Therapy (CBT), called Stepped Care CBT, that requires fewer therapy visits and utilizes family members as active components in treatment. Children and families who are interested must complete an initial assessment to determine eligibility.

Eligible participants must be between 8 and 17 years of age and have a primary diagnosis of Obsessive Compulsive Disorder. Once eligibility is determined, participants will be randomly assigned to receive Stepped Care CBT or standard CBT. Those receiving Stepped Care CBT begin treatment in “Step One” which includes 3 sessions with a therapist over the course of 6 weeks while being coached through a take-home workbook. If after 6 weeks it is determined by the research team that insufficient progress has been made, participants progress to “Step Two” which includes 9 additional therapy sessions over 9 weeks. Those receiving standard CBT will receive weekly therapy sessions for 12 weeks. Please contact Brittney Dane at (727) 767-7427 for more information.

Principal Investigator: Adam B. Lewin, PhD, ABPP

Parent-led Behavioral Treatment for Young Children with Problematic Anxiety

The purpose of this research study is to examine the effectiveness of a parent-led behavioral treatment for children ages 3 to 7 years old with problematic anxiety. Children and families who are interested must complete an initial assessment to determine eligibility. Once eligibility is determined, participants will be randomly assigned to receive 5 weeks of the parent-led behavioral treatment or a 5 week wait-list condition (followed by 5 weeks of the therapy intervention). Please call (727) 767-8230 for more information.

Principal Investigator: Adam B. Lewin, PhD, ABPP